Antares Pharma (ATRS) Misses Q4 EPS by 3c

Antares Pharma (NASDAQ: ATRS) reported Q4 EPS of ($0.08), $0.03 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $8.4 million versus the consensus estimate of $8.5 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• Ericsson (ERIC) Tops Q2 EPS by 3c
• Morgan Stanley Downgrades Tryg A/S (TRYG:DC) (TGVSF) to Underweight